Plasma clusterin levels and the rs11136000 genotype in individuals with mild cognitive impairment and Alzheimer's disease

Current Alzheimer Research

Volumn 10, Issue 9, 2013, Pages 973-978

  Mullan, Gemma M ^a   McEneny, Jane ^a   Fuchs, Marc ^a   McMaster, Cyril ^a   Todd, Stephen ^b   McGuinness, Bernadette ^a   Henry, Mark ^a   Passmore, A Peter ^a   Young, Ian S ^a   Johnston, Janet A ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ALTNAGELVIN HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; Clusterin; Mild cognitive impairment; rs 11136000

Indexed keywords

CLUSTERIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CLUSTERIN; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84888252977     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/15672050113106660162     Document Type: Article

References (27)

1. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41: 1088-1093 (2009).
2. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41: 1094-1099 (2009).
3. Blaschuk O, Burdzy K, Fritz IB. Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. J Biol Chem 258: 7714-7720 (1983).
4. Wong P, Taillefer D, Lakins J, Pineault J, Chader G, Tenniswood M. Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegenera-tion. Eur J Biochem 221: 917-925 (1994).
5. Nuutinen T, Suuronen T, Kauppinen A, Salminen A. Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev 61: 89-104 (2009).
6. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923 (1993).
7. Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neu-rol 10: 241-252 (2011).
8. Schaefer EJ, Foster DM, Jenkins LL, Lindgren FT, Berman M, Levy RI, et al. The composition and metabolism of high density lipoprotein subfractions. Lipids 14: 511-522. (1979).
9. de Silva HV, Stuart WD, Duvic CR, Wetterau JR, Ray MJ, Ferguson DG, et al. A 70-kDa apolipoprotein designated ApoJ is a marker for subclasses of human plasma high density lipoproteins. J Biol Chem 265: 13240-13247 (1990).
10. Matsubara E, Frangione B, Ghiso J. Characterization of apolipo-protein J-Alzheimer's A beta interaction. J Biol Chem 270: 7563-7567 (1995).
11. Zlokovic BV, Martel CL, Mackic JB, Matsubara E, Wisniewski T, McComb JG, et al. Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid beta. Biochem Biophys Res Commun 205: 1431-1437 (1994).
12. Zlokovic BV. Clearing amyloid through the blood-brain barrier. J Neurochem 89: 807-811 (2004).
13. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 110: 1129-1134 (2009).
14. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 63: 287-303 (2009).
15. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease; recommendations from the National Institute of Aging-Alzheimer's association workgroups on diagnostic guide-lines for Alzheimer's disease. Alzheimer's and dementia 7: 270-279v.
16. Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM. Plasma clusterin and the risk of Alzheimer disease. JAMA 305: 1322-1326 (2011).
17. Schurmann B, Wiese B, Bickel H, Weyerer S, Riedel-Heller SG, Pentzek M, et al. Association of the Alzheimer's disease clusterin risk allele with plasma clusterin concentration. J Alzheimers Dis 25: 421-424 (2011).
18. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198 (1975).
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stad-lan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944 (1984).
20. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256: 240-246 (2004).
21. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215 (1988).
22. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: a toolset for whole-genome association and population-based linkage analysis. Am J Hum Genet 81: 559-575 (2007).
23. Thambisetty M, An Y, Kinsey A, Koka D, Saleem M, Guntert A, et al. Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage 59: 212-217 (2012).
24. Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 67: 739-748 (2010).
25. IJsselstijn L, Dekker LJ, Koudstaal PJ, Hofman A, Sillevis Smitt PA, et al. Serum clusterin levels are not increased in presympto-matic Alzheimer's disease. J Proteome Res 10: 2006-2010 (2011).
26. Tanzi, RE, Moir, RD, Wagner SL. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 43: 605-608 (2004).
27. Wang YJ, Zhou HD, Zhou XF. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Dis-cov. Today 11: 931-938 (2006).